Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)
Pablo Matar(Hebron University), José Baselga(Universitat Autònoma de Barcelona)
Cited by 277
Related Papers
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
|JNCI Journal of the National Cancer Institute|2007|876
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
|Journal of Clinical Oncology|2005|409
Targeted therapies for breast cancer
|Journal of Clinical Investigation|2011|371
Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
|Molecular Cancer Therapeutics|2011|52